What question did this study set out to answer?

Investigate the therapeutic effects and molecular mechanisms of interleukin-31 in attenuating sepsis and septic shock via inflammasome and cytokine regulation.

May 17, 2018Experimental and Therapeutic MedicineOpen Access

Effect of interleukin‑31 on septic shock through regulating inflammasomes and interleukin‑1β

View Full Paper

Ask AI

Bookmark

Authors

XGXuyun GuCapital Medical University WCWei ChenHebei Medical University XZXishan ZhuPeking University First Hospital

Discussion

Member takes

Implication

Preclinical study demonstrates that interleukin-31 decreases mortality and curbs inflammatory signaling in septic models, suggesting therapeutic potential for septic shock management.

Key Points

Investigate the therapeutic effects and molecular mechanisms of interleukin-31 in attenuating sepsis and septic shock via inflammasome and cytokine regulation.
Evaluated survival rates and serum cytokine profiles in mice with sepsis induced by lipopolysaccharide challenge or cecal ligation and puncture.
Assessed interleukin-1β release and inflammasome activation in lipopolysaccharide-primed peritoneal macrophages and human peripheral blood monocytes treated with interleukin-31.
Analyzed the interleukin-31 signaling axis in human THP-1 cells using neutralizing antibodies against interleukin-31 and its receptor.
Interleukin-31 administration reduced mortality and circulating inflammatory cytokine levels in lipopolysaccharide-induced sepsis, while decreasing peritoneal interleukin-1β in both sepsis models.
Treatment with interleukin-31 suppressed NLRP3 gene transcription and blocked ATP-induced interleukin-1β release in peritoneal macrophages, whereas antibody blockade of interleukin-31 signaling in THP-1 cells enhanced NLRP3 expression and interleukin-1β activation.
In human peripheral blood monocytes, interleukin-31 inhibited the NLRP1 inflammasome rather than NLRP3, resulting in decreased tumor necrosis factor-α secretion.

Cite This Study

Gu et al. (2018) studied this question.

synapsesocial.com/papers/6aaf85e79d8bf8b9a3a5f7ae https://doi.org/10.3892/etm.2018.6181

View Full Paper

Ask AI

Bookmark

Implication

Preclinical study demonstrates that interleukin-31 decreases mortality and curbs inflammatory signaling in septic models, suggesting therapeutic potential for septic shock management.

Effect of interleukin‑31 on septic shock through regulating inflammasomes and interleukin‑1β

Discussion

Member takes

Implication

Key Points

Cite This Study

Effect of interleukin‑31 on septic shock through regulating inflammasomes and interleukin‑1β

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider